Tirzepatide Safety Questions: What Studies Report

Tirzepatide is a single peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. A 2020 laboratory characterisation described the molecule as an imbalanced and biased dual agonist, with researchers reporting greater relative potency at the GIP receptor than at the GLP-1 receptor and biased signalling behaviour in cell-based assays (PMID 32730231). That receptor pharmacology is the starting point for most published safety discussion, because the adverse events recorded in trials — overwhelmingly gastrointestinal — resemble those long associated with incretin receptor agonism.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or treatment decision. Nothing here describes what any individual should do, and nothing here substitutes for the full prescribing information of an approved product.

Why hyperthyroidism appears in tirzepatide searches

One of the most common safety searches is whether tirzepatide is contraindicated in hyperthyroidism. The confusion is understandable: labelling for approved tirzepatide products in the United States carries a boxed warning about thyroid C-cell tumours observed in rodents and lists a personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2, as a contraindication. Those are regulatory statements about a specific thyroid cancer risk signal, not about thyroid hormone excess such as Graves' disease, toxic nodular goitre or subclinical hyperthyroidism.

A 2023 drug monograph reviewed tirzepatide as a newly approved dual GIP and GLP-1 receptor agonist for type 2 diabetes and summarised the product's place among incretin therapies (PMID 36751934). A 2022 systematic update likewise compiled the pharmacology and trial programme in one place (PMID 36498958). Neither of those reviews, and none of the randomised trials summarised below, reported outcomes in a population defined by hyperthyroidism. On that specific question, the published literature cited here is silent — a gap, not a reassurance and not a warning.

Gastrointestinal adverse events: What Studies Report

Across the trial programme, digestive complaints dominated the adverse-event tables. In SURPASS-1, a double-blind phase 3 trial, researchers randomised participants with type 2 diabetes to tirzepatide 5 mg, 10 mg or 15 mg once weekly or placebo for 40 weeks, and reported that the most frequent adverse events were mild-to-moderate, transient gastrointestinal events including nausea, diarrhoea and vomiting (PMID 34186022).

The obesity trials described the same pattern. SURMOUNT-4 used a 36-week open-label lead-in at a maximum tolerated dose of 10 mg or 15 mg once weekly before randomising participants to continue tirzepatide or switch to placebo for a further 52 weeks; the study reported that the most common adverse events were gastrointestinal, mostly mild to moderate, and that they occurred primarily during the dose-escalation phase of the lead-in period (PMID 38078870).

In the 2025 head-to-head comparison of tirzepatide and semaglutide in adults with obesity, participants received the maximum tolerated dose of tirzepatide (10 mg or 15 mg once weekly) or semaglutide (1.7 mg or 2.4 mg once weekly) for 72 weeks. Researchers reported that gastrointestinal adverse events were the most common in both groups and were predominantly mild to moderate in severity (PMID 40353578). A 2025 pharmacotherapy review of tirzepatide for overweight and obesity management summarised the same tolerability theme across the SURMOUNT programme (PMID 39632534).

Where in treatment the events clustered

The timing detail matters for how the literature is read. SURMOUNT-4 located most gastrointestinal events in the escalation portion of its 36-week lead-in rather than during the 52-week randomised maintenance phase (PMID 38078870), and SURPASS-1 characterised its gastrointestinal events as transient (PMID 34186022). Published trials therefore describe a front-loaded tolerability profile rather than a constant background rate.

Hypoglycaemia and background diabetes therapy: What Studies Report

Hypoglycaemia risk in the published record depended heavily on what else participants were taking. SURPASS-1 studied tirzepatide as monotherapy in people with type 2 diabetes not on other glucose-lowering drugs, and the investigators reported no severe hypoglycaemia in the trial (PMID 34186022).

SURPASS-5 examined a different setting: tirzepatide 5 mg, 10 mg or 15 mg once weekly, or placebo, added to titrated insulin glargine over 40 weeks in adults with type 2 diabetes (PMID 35133415). The study reported greater glycaemic improvement with tirzepatide added to insulin, and hypoglycaemia was documented in participants on that insulin background — an outcome the trial design makes directly relevant to anyone reading about combination therapy rather than monotherapy.

Appetite, energy intake and body composition: What Studies Report

A mechanistic trial in people with type 2 diabetes measured what tirzepatide did to eating behaviour. Researchers reported that tirzepatide, titrated up to 15 mg once weekly, reduced appetite, reduced energy intake and reduced fat mass compared with placebo (PMID 36857477). These findings are frequently cited in safety discussions because reduced intake is the plausible mechanism linking the drug to both the intended metabolic effects and to the nausea and vomiting reported in the phase 3 programme (PMID 34186022).

Liver disease and steatohepatitis: What Studies Report

A 2024 phase 2 randomised trial studied tirzepatide 5 mg, 10 mg or 15 mg once weekly versus placebo for 52 weeks in participants with metabolic dysfunction–associated steatohepatitis (MASH) and liver fibrosis, and the study reported that tirzepatide was more effective than placebo with respect to resolution of MASH without worsening of fibrosis (PMID 38856224). The most commonly reported adverse events in that trial were gastrointestinal, consistent with the wider programme (PMID 38856224). This is a phase 2 result with a histological endpoint at 52 weeks, not a long-term outcomes trial.

Heart failure with preserved ejection fraction: What Studies Report

A 2025 JAMA analysis examined semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction (PMID 40886075). It is one of the few published sources addressing this specific cardiac population and incretin agonists side by side, and readers evaluating cardiovascular safety questions generally have to weigh the design and population of that analysis rather than assume its findings transfer to other cardiac phenotypes.

Discontinuation and weight regain: What Studies Report

SURMOUNT-4 is the trial most often cited on what happened when treatment stopped. After the 36-week open-label lead-in, the study reported that participants randomised to continue tirzepatide achieved additional weight reduction over the following 52 weeks, whereas those switched to placebo regained a substantial proportion of the weight lost during the lead-in (PMID 38078870). This is a maintenance finding about the trial population, not a prediction about any individual, and the trial did not report a withdrawal syndrome beyond weight regain.

Children and adolescents: What Studies Report

SURPASS-PEDS was a randomised, double-blind, placebo-controlled phase 3 trial of tirzepatide in children and adolescents with type 2 diabetes (PMID 40975112). The published report described efficacy and safety in that younger population, with a tolerability picture in which gastrointestinal events again featured among the most frequently reported adverse events (PMID 40975112). Paediatric evidence remains far smaller in volume than the adult programme.

Trials at a glance

Populations and questions with no data in this literature

Reporting absence honestly is part of reading a safety literature. Among the papers summarised on this page, none reported dedicated findings for:

• Hyperthyroidism of any cause — Graves' disease, toxic multinodular goitre, thyroiditis or subclinical thyrotoxicosis were not the subject of any cited trial or review.
• Thyroid eye disease or other extrathyroidal manifestations.
• Pregnancy or lactation.
• Type 1 diabetes — the diabetes trials cited here enrolled type 2 diabetes (PMID 34186022).
• Research-chemical or unapproved preparations — every dose reported above came from a regulated clinical trial of a defined product, not from material sold for laboratory use.

Where a question has no published answer, the honest summary is that the evidence does not exist in the sources reviewed, and no inference in either direction should be drawn from silence.

How to read the tolerability numbers

1. Dose and duration are inseparable from the event rate. Escalation schedules differed between trials, and SURMOUNT-4 explicitly located most gastrointestinal events in its escalation window (PMID 38078870).
2. Background therapy changes the risk profile. Monotherapy and insulin-combination trials produced different hypoglycaemia pictures (PMID 34186022, PMID 35133415).
3. Trial populations are selected. Randomised trials exclude many comorbidities, so their adverse-event tables describe the enrolled population only.
4. Reviews summarise, they do not add data. The 2022 systematic update and 2025 pharmacotherapy review compile the same primary trials (PMID 36498958, PMID 39632534).

Anyone with a thyroid condition, cardiac disease, liver disease or diabetes who has questions about incretin pharmacology should raise them with a licensed clinician who can read the prescribing information alongside an individual medical history. This page reports what specific studies published, in the doses and durations they used, and does not recommend, endorse or discourage any course of action.

References

• Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (JCI Insight, 2020)
• Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial (Lancet, 2021)
• Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial (JAMA, 2022)
• Tirzepatide: A Systematic Update (International Journal of Molecular Sciences, 2022)
• New Drug: Tirzepatide (Mounjaro) (The Senior Care Pharmacist, 2023)
• Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes (Diabetes Care, 2023)
• Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial (JAMA, 2024)
• Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis (New England Journal of Medicine, 2024)
• Tirzepatide for overweight and obesity management (Expert Opinion on Pharmacotherapy, 2025)
• Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (New England Journal of Medicine, 2025)
• Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (JAMA, 2025)
• Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial (Lancet, 2025)